The therapeutic community is buzzing with anticipation surrounding retatrutide, a new dual GIP and GLP-1 target that’s exhibiting significant efficacy in clinical trials for addressing obesity. Unlike some available weight loss approaches, retatrutide appears to deliver a more substantial loss in body mass and enhance metabolic markers, particula